Old Web
English
Sign In
Acemap
>
Paper
>
PMO-15 Transitioning from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease (TRAVELESS)
PMO-15 Transitioning from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease (TRAVELESS)
2021
Esther Ventress
Sohail Rahmany
David S. Young
Marion Bettey
Clare Harris
Helen Moyses
Trevor R.F. Smith
Richard Felwick
Markus Gwiggner
Fraser Cummings
Keywords:
Gastroenterology
Inflammatory bowel disease
in patient
Internal medicine
Medicine
Vedolizumab
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]